๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Solid Tumor Cancer
Clinical trial register · China

Solid Tumor Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 4 Shanghai 4 Jinan 4 Chengdu 2 Fuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing4 Shanghai4 Jinan4 Chengdu2 Fuzhou2
All 15 locations
Target enrolment
to

Solid Tumor Cancer trials in China

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
NCT07583654mRNA Vaccine, Solid Tumor Cancer, Peptides, Cancer Metastatic
West China Hospital
Phase 1
18
Chengdu
2026-07-13
Recruiting
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07603479Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
Jecho Biopharmaceuticals Co., Ltd.
Phase 1
14
Beijing
2026-06-25
Recruiting
QLS5212 for Participants With Advanced Solid Tumors
NCT07467629Solid Tumor Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1
100
Taiyuan
2026-05-11
Recruiting
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
NCT07441174Solid Tumor Cancer, PDAC
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Active, closed
Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol
NCT07257497Solid Tumor Cancer
West China Hospital
Phase 1
20
Chengdu
2025-12-01
Recruiting
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
NCT07269899Solid Tumor Cancer, Cancer
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-11-25
Recruiting
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
NCT07146672Solid Tumor Cancer
Shanghai Cell Therapy Group Co.,Ltd
Phase 1/2
12
Shanghai
2025-07-31
Not yet open
A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT07046780Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced
PENG YUAN
Observational
90
Beijing
2025-07-30
Recruiting
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07070518Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
GV20 Therapeutics
Phase 1/2
350
Beijing, Shanghai
2025-07-11
Recruiting
Imatinib and Trametinib for KRAS-mutated Solid Tumor
NCT06962254Solid Tumor Cancer
China Medical University Hospital
Phase 1
10
2025-05-10
Recruiting
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
NCT06848699Solid Tumor Cancer, Non Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 1/2
105
Hunan, Jinan, Chongqing
2025-02-25
Recruiting
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
NCT06883539Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
LaunXP Biomedical Co., Ltd.
Phase 1
24
2024-12-31
Recruiting
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
NCT06682117Treatment, Neoantigen, Vaccine, Solid Tumor Cancer
Fudan University
Not applicable
9
Shanghai
2024-11-15
Not yet open
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
NCT06649448Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
Shandong Cancer Hospital and Institute
Not applicable
200
Jinan
2024-10-10
Recruiting
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Recruiting
A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers
NCT07264803Solid Tumor Malignancies, Solid Tumor Cancer
Qilu Hospital of Shandong University
Phase 2
35
Jinan
2024-03-01
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/solid-tumor-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies listing the condition Solid Tumor Cancer.

How many Solid Tumor Cancer trials are recruiting in China?

13 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Solid Tumor Cancer), 16 studies
PhaseStudiesRecruitingShare
Phase 18750%
Phase 1/24425%
Not applicable2112.5%
Observational106.3%
Phase 2116.3%

Most active sponsors

Lead sponsors with the most studies (Solid Tumor Cancer)
Lead sponsorStudiesRecruiting
West China Hospital21
China Medical University Hospital11
Fudan University11
GV20 Therapeutics11
InxMed (Shanghai) Co., Ltd.11
Jecho Biopharmaceuticals Co., Ltd.11
Jun Zhou11
LaunXP Biomedical Co., Ltd.11
PENG YUAN10
Qilu Hospital of Shandong University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.